In this sense, to evaluate whether FPR2 was involved in the cytoprotective effect of HN in GBM cells, we evaluated the effect of HNGF6A in human GBM U251-MG cells as well as in mIDH and wtIDH murine glioma neurospheres treated with cisplatin in the presence of a peptidic FPR2 receptor antagonist, WRW4 [22,23]. This evidence concerns the gene FPR2 and central nervous system cancer.